ArriVent BioPharma, Inc. Common Stock (AVBP) NASDAQ
$22.39 (1.41) (-5.91%)
Market Cap: $751.82M
As of 09/13/24 11:43 AM EDT. Market open.
ArriVent BioPharma, Inc. Common Stock (AVBP)
NASDAQ
$22.39
(1.41) (-5.91%)
Market Cap: $751.82M
As of 09/13/24 11:43 AM EDT. Market open.
Add to Portfolio
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops ... read more
COMPANY PROFILE
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Zhengbin Yao Ph.D.
Full Time Employees
40
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Zhengbin Yao Ph.D.
Full Time Employees
40
URL
Address
18 Campus Boulevard, Newtown Square, 19073.
PRICE CHART FOR ARRIVENT BIOPHARMA, INC. COMMON STOCK
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$23.80
Previous Close
$23.79
Days Range
$22.30 - $24.31
52 week range
$14.35 - $30.99
Volume
111,218
Avg. Volume (30 days)
138,990
Market Cap
$751.82M
Dividend Yield
-
P/E
(10.04)
Shares Outstanding
33,585,890
Open
$23.80
Previous Close
$23.79
Days Range
$22.30 - $24.31
52 week range
$14.35 - $30.99
Volume
111,218
Avg. Volume (30 days)
138,990
Market Cap
$751.82M
Dividend Yield
-
P/E
(10.04)
Shares Outstanding
33,585,890
FINANCIAL STATEMENTS FOR ARRIVENT BIOPHARMA, INC. COMMON STOCK
LOADING...
Open in: 
Open in:
INSIDER TRANSACTIONS FOR ARRIVENT BIOPHARMA, INC. COMMON STOCK
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| HILLHOUSE INVESTMENT MANAGEMENT, LTD. | 10% Owner | Jan 30, 2024 | Buy | $18.00 | 555,555 | 9,999,990 | 4,484,672 | Feb 01, 2024, 04:47 PM |
| ORBIMED ADVISORS LLC | Director | Jan 30, 2024 | Buy | $18.00 | 444,444 | 7,999,992 | 1,513,664 | Jan 31, 2024, 04:12 PM |
| GORDON CARL L | Director | Jan 30, 2024 | Buy | $18.00 | 444,444 | 7,999,992 | 1,513,664 | Jan 31, 2024, 04:11 PM |
| HEALY JAMES | Director | Jan 30, 2024 | Buy | $18.00 | 444,444 | 7,999,992 | 1,696,752 | Jan 31, 2024, 04:10 PM |
Buy
Sale
Option Exercise
| Owner | Relationship | Date | Value($) |
| HILLHOUSE INVESTMENT MANAGEMENT, LTD. | 10% Owner | 01/30/2024 | 9,999,990 |
| ORBIMED ADVISORS LLC | Director | 01/30/2024 | 7,999,992 |
| GORDON CARL L | Director | 01/30/2024 | 7,999,992 |
| HEALY JAMES | Director | 01/30/2024 | 7,999,992 |
FUNDS WITH A POSITION IN ARRIVENT BIOPHARMA, INC. COMMON STOCK
| Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
|---|---|---|---|---|
| HHLR ADVISORS, LTD. | 4,484,672 | 2.05% | 14.14% | Other |
| ORBIMED ADVISORS LLC | 3,027,328 | 1.11% | No change | Other |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,712,703 | 1.17% | 9.53% | Growth At A Reasonable Price |
| BLACKROCK INC. | 663,265 | 0.00028% | 1.29% | Other |
| GEODE CAPITAL MANAGEMENT, LLC | 234,944 | 0.00038% | 4.4% | Other |
| FARALLON CAPITAL MANAGEMENT LLC | 151,768 | 0.01% | Exited | Event Driven, Value |
| OCONNOR, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS (LLC) | 26,181 | 0.03% | Exited | Value |
| ALPS ADVISORS INC | 26,139 | 0.00333% | New | Other |
| BLACKSTONE INC. | 25,000 | 0.0018% | Exited | Other |
BUYBACK ANNOUNCEMENT(S) FOR ARRIVENT BIOPHARMA, INC. COMMON STOCK
LOADING...